BridGene Biosciences

BridGene Biosciences is an innovative biotechnology company dedicated to discovering and developing small molecule drugs targeting traditionally "undruggable" targets, paving new pathways for disease treatment. The company’s self-developed IMTAC™ chemoproteomics platform can screen the entire proteome in living cells, identifying high-value small molecule drug candidates for targets that are conventionally considered "undruggable."